Back to state act
Description
On 19 December 2025, the United States announced an agreement with Novartis providing the company with three years of tariff relief from the potential Section 232 pharmaceutical tariffs. In exchange, ...
Sign in to see full description
Intervention Details
Intervention Type
Import tariff
MAST Chapter
Tariff measures
Implementation date
No implementation date
Revocation date
No revocation date
Implementation level
National
Affected flow
Inward
Announced as temporary
No
Eligible firms
firm-specific
Affected Trading Partners
Table
Affected Sectors
Sign in to access 1 sectors
Affected Products
Sign in to access 5 products
Threads
See all
This intervention is not part of any Thread yet.